HCC Recurrence Risk Calculator- Free Hepatocellular Carcinoma Recurrence Prediction Tool

About This HCC Recurrence Risk Calculator

This hepatocellular carcinoma recurrence risk calculator is designed for patients, caregivers, and healthcare professionals seeking to estimate the probability of liver cancer recurrence after curative-intent treatment. The tool incorporates validated clinical scoring systems including the RETREAT score for post-transplant risk stratification and the AFP-score for pre-treatment and post-treatment risk assessment, allowing comprehensive evaluation of recurrence risk based on tumor size, number, vascular invasion, alpha-fetoprotein levels, tumor differentiation grade, and cirrhosis severity.

The calculator utilizes the RETREAT scoring methodology developed and validated across multiple major transplant centers and confirmed by the United Network for Organ Sharing database, along with the AFP-score system and published clinical risk factor data. Risk estimates follow published outcome data from multicenter retrospective and prospective studies, including recurrence rates stratified by RETREAT score category and treatment-specific outcomes from large international cohorts. The tool references guidelines from the AASLD, EASL, and the Barcelona Clinic Liver Cancer staging system.

Key features include a three-way treatment comparison showing estimated recurrence rates for liver transplantation, resection, and radiofrequency ablation side by side, horizontal zone bar visualizations showing where your RETREAT and AFP scores fall on the clinical risk spectrum, and personalized surveillance recommendations that adapt based on your individual risk level. The grouped overlay bar chart allows direct visual comparison of recurrence timelines across all three treatment modalities for your specific tumor profile.

HCC Recurrence Risk Calculator: Complete Guide to Predicting Hepatocellular Carcinoma Recurrence After Treatment

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and ranks as the third leading cause of cancer-related death worldwide. While curative-intent treatments such as liver resection, liver transplantation, and radiofrequency ablation offer the best chance of long-term survival, tumor recurrence remains the most significant challenge in HCC management. Recurrence rates after liver resection range from 50% to 70% at five years, and even after liver transplantation, approximately 10% to 15% of recipients experience HCC recurrence. Understanding and predicting recurrence risk is essential for optimizing surveillance strategies, guiding adjuvant therapy decisions, and improving patient outcomes.

This comprehensive guide covers the clinical factors that influence HCC recurrence, the validated scoring systems used to estimate recurrence risk, and how to interpret the results from this calculator. The information presented draws on major multicenter studies, international guidelines from the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Barcelona Clinic Liver Cancer (BCLC) staging system.

Understanding HCC Recurrence Patterns

HCC recurrence after curative treatment follows two distinct patterns with different underlying mechanisms and clinical implications. Early recurrence, generally defined as tumor recurrence within the first 24 months after treatment, is primarily driven by tumor-related factors. These include intrahepatic metastasis from the original tumor, residual microscopic disease, and aggressive tumor biology characterized by vascular invasion, poor differentiation, and elevated biomarkers. Early recurrence accounts for approximately 60% to 70% of all recurrences and tends to carry a worse prognosis.

Late recurrence, occurring more than 24 months after initial treatment, is predominantly related to the underlying chronic liver disease. This pattern represents de novo carcinogenesis arising from the cirrhotic or diseased liver parenchyma rather than metastasis from the original tumor. Risk factors for late recurrence include the severity of liver fibrosis or cirrhosis, ongoing viral hepatitis activity, and persistent inflammation. The distinction between early and late recurrence has important implications for surveillance intensity and potential salvage treatment options.

Major Risk Factors for HCC Recurrence

Multiple clinical, pathological, and laboratory factors have been identified as independent predictors of HCC recurrence. These factors form the basis of the various scoring systems and risk calculators used in clinical practice.

Tumor Size: Larger tumors carry a significantly higher risk of recurrence. Tumors exceeding 5 cm in diameter are associated with increased rates of microvascular invasion, satellite nodules, and poor histological differentiation. The Milan criteria, which limit transplant candidacy to patients with a single tumor of 5 cm or less or up to three tumors each 3 cm or less, were established based on the strong relationship between tumor burden and recurrence risk. Studies have shown that 5-year recurrence-free survival drops from approximately 50% to 60% for tumors under 3 cm to less than 20% for tumors exceeding 5 cm after liver resection.

Tumor Number: The presence of multiple tumors (multinodularity) is a strong predictor of recurrence and reflects more advanced disease biology. Multiple tumors may represent either intrahepatic metastases from a primary tumor or multicentric carcinogenesis from the underlying liver disease. Both scenarios carry higher recurrence risk compared to solitary tumors. The total tumor burden, typically expressed as the sum of the largest tumor diameter plus the number of tumors, is used in the RETREAT scoring system as a composite measure of disease extent.

Vascular Invasion: Microvascular invasion (MVI) is one of the strongest independent predictors of HCC recurrence across all treatment modalities. MVI refers to the presence of tumor cells within small hepatic vessels visible only on microscopic examination and cannot be reliably detected by preoperative imaging. The 5-year recurrence rate in patients with MVI after liver resection is reported as high as 70%, compared to approximately 30% to 40% in patients without MVI. Macrovascular invasion, visible on imaging, indicates even more aggressive disease and is associated with very poor prognosis.

Alpha-Fetoprotein (AFP): Serum AFP level is the most widely used and validated biomarker for predicting HCC recurrence. AFP is incorporated into multiple scoring systems including the RETREAT score and the AFP-score. Key clinical thresholds include AFP below 20 ng/mL (low risk), AFP between 20 and 99 ng/mL (moderate risk), AFP between 100 and 999 ng/mL (high risk), and AFP at or above 1,000 ng/mL (very high risk). Elevated AFP before treatment correlates with vascular invasion, poor tumor differentiation, and microscopic residual disease. Rising AFP after treatment is often the first indicator of recurrence.

Tumor Grade: Histological differentiation grade, typically assessed using the Edmondson-Steiner classification, is an important predictor of recurrence. Poorly differentiated tumors (Grade III-IV) are associated with more aggressive biological behavior, higher rates of vascular invasion, and increased recurrence risk. Well-differentiated tumors (Grade I-II) generally carry a more favorable prognosis. The Model of Recurrence After Liver Transplantation (MORAL) score identifies Grade IV tumors as one of the highest-weight predictive factors.

Cirrhosis Status and Liver Function: The underlying liver condition significantly influences both early and late recurrence risk. Patients with established cirrhosis face a dual risk: recurrence from the treated tumor and development of new tumors from the cirrhotic liver parenchyma. Child-Pugh classification, MELD score, and fibrosis markers such as the FIB-4 index help quantify this risk. The ongoing presence of active viral hepatitis (hepatitis B or C) without adequate antiviral therapy further increases de novo HCC risk.

Treatment Type: The choice of treatment modality significantly impacts recurrence patterns and rates. Liver transplantation offers the lowest recurrence rates (10-15% at 5 years) because it removes both the tumor and the underlying diseased liver. Liver resection provides good long-term survival but is associated with higher recurrence rates (50-70% at 5 years) because the remaining cirrhotic liver continues to harbor carcinogenic potential. Radiofrequency ablation (RFA) achieves local tumor control comparable to resection for small tumors but has higher local recurrence rates for larger tumors or those in difficult locations.

The RETREAT Score: Predicting Recurrence After Liver Transplantation

The Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score is the most widely validated post-transplant risk stratification tool for HCC. Developed by Mehta et al. using data from over 1,000 patients at three major academic transplant centers (University of California-San Francisco, Mayo Clinic Rochester, and Mayo Clinic Jacksonville), RETREAT incorporates three variables that were independently associated with HCC recurrence on multivariable analysis: microvascular invasion on explant pathology, AFP level at the time of transplant, and the sum of the largest viable tumor diameter plus the number of viable tumors on the explant specimen.

The RETREAT score ranges from 0 to 8 points and provides excellent risk stratification. In the original development and validation cohorts, patients with a RETREAT score of 0 had less than 3% risk of recurrence at 5 years, while those with scores of 5 or higher had greater than 75% recurrence risk at 5 years. The concordance statistic (C-statistic) of 0.77 in the development cohort and 0.82 in the validation cohort demonstrates strong discriminative ability. Subsequent validation in the United Network for Organ Sharing (UNOS) database of over 3,200 patients confirmed these findings, with 3-year recurrence probabilities of 1.6% for a score of 0 and 29% for scores of 5 or higher.

A key limitation of the RETREAT score is that two of its three components (microvascular invasion and viable tumor burden on explant) can only be assessed after the transplant has been performed. This makes it primarily a post-transplant risk stratification tool rather than a pre-transplant selection tool. However, it is invaluable for determining the intensity of post-transplant surveillance and identifying patients who may benefit from adjuvant therapy. Prospective multicenter validation published in 2025 demonstrated that patients with RETREAT scores of 0, 3, and 5 or greater had 3-year recurrence-free survival rates of 99.4%, 84.1%, and 55.6% respectively.

The AFP-Score: Biomarker-Based Risk Prediction

The AFP-score (also known as the French AFP model) was developed as a biomarker-based scoring system that combines AFP level with tumor morphological features. Originally designed for liver transplant candidate selection, it has since been validated for predicting recurrence after both transplantation and resection. The AFP-score is calculated by combining points assigned to the serum AFP level (0 points for under 100 ng/mL, 1 point for 100-1,000 ng/mL, 4 points for over 1,000 ng/mL), the largest tumor diameter (0 points for 3 cm or less, 1 point for 3.1-6 cm, 2 points for over 6 cm), and the number of nodules (0 points for 1-3, 2 points for 4 or more). A score greater than 2 indicates a greater risk of HCC recurrence.

Research has demonstrated that the AFP-score effectively differentiates between low-risk and high-risk groups for recurrence after resection, with median time to recurrence of 21.8 months in the low-risk group versus 8.3 months in the high-risk group. The advantage of the AFP-score over the RETREAT score is that all three components can be assessed preoperatively, making it useful for both pre-treatment decision-making and post-treatment risk stratification.

Clinical Risk Score for Recurrence After Resection

The Clinical Risk Score (CRS) was developed specifically for predicting recurrence after curative-intent liver resection. Unlike the RETREAT score, the CRS focuses on factors relevant to the resection setting. Key variables in various CRS models include tumor size, number of tumors, presence of vascular invasion (both micro and macro), serum AFP level, and margin status. Advanced T-stage classification, indicating larger tumor burden or invasion of adjacent structures, is also significantly associated with both intrahepatic and extrahepatic recurrence.

For liver resection patients, independent prognostic factors consistently identified across multiple studies include preoperative AFP level greater than 400 ng/mL, macrovascular invasion visible on imaging, microscopic portal vein thrombosis, multiple tumor nodules, and tumor size exceeding 5 cm. The combination of these factors can stratify patients into low, moderate, and high risk groups with markedly different 5-year outcomes. For example, one large multicenter study showed 5-year overall survival of 65.7% for low-risk, 49.5% for moderate-risk, and 17.0% for high-risk patients after resection.

Milan Criteria and Beyond: Transplant Selection and Recurrence

The Milan criteria, established in 1996, remain the international benchmark for selecting liver transplant candidates with HCC. These criteria limit transplantation to patients with either a single tumor of 5 cm or less, or up to three tumors each 3 cm or less, without macrovascular invasion or extrahepatic spread. Patients meeting Milan criteria at transplant have 5-year overall survival rates of 65% to 80% and recurrence rates of approximately 10% to 15%.

However, several expanded criteria have been proposed to allow more patients access to transplantation while maintaining acceptable outcomes. The University of California San Francisco (UCSF) criteria permit a single tumor up to 6.5 cm or up to three tumors with the largest no more than 4.5 cm and total tumor diameter not exceeding 8 cm. The Up-to-7 criteria (sum of the largest tumor diameter in centimeters plus the number of tumors does not exceed 7) have been validated in large international cohorts. These expanded criteria increase the eligible patient pool while accepting modestly higher recurrence rates.

Importantly, approximately 15% to 20% of patients who meet Milan criteria on preoperative imaging are found to exceed these criteria on explant pathology due to understaging. This understaging phenomenon significantly predicts recurrence, with hazard ratios of approximately 3.5 for recurrence compared to patients whose explant pathology confirms Milan-in status.

Recurrence Risk After Radiofrequency Ablation

Radiofrequency ablation (RFA) is a widely used curative-intent treatment for early-stage HCC, particularly in patients with small tumors and impaired liver function that precludes resection. RFA achieves complete tumor necrosis by applying thermal energy through a percutaneous probe. For tumors smaller than 2 cm, RFA achieves local control rates comparable to surgical resection, with complete response rates exceeding 95%.

However, the recurrence pattern after RFA differs from surgical approaches. Local tumor progression (recurrence at or adjacent to the ablation site) occurs in approximately 5% to 15% of cases and is more common with larger tumors, tumors adjacent to blood vessels (due to the heat-sink effect), and insufficient ablation margins. Distant intrahepatic recurrence, representing either metastasis or de novo tumor formation, occurs at rates similar to those seen after resection, reflecting the persistent carcinogenic potential of the underlying liver disease.

A large Korean study of over 1,400 patients with early-stage HCC treated with resection or RFA reported cumulative recurrence rates of 39.7% at 2 years, 60.3% at 5 years, and 71.0% at 10 years. Risk factors for recurrence within the first 5 years included male sex, higher ALBI grade (reflecting poorer liver function), higher AFP levels, multiple tumors, and treatment with RFA rather than resection. For patients who remained recurrence-free at 5 years, independent risk factors for subsequent recurrence were male sex, higher FIB-4 scores, and elevated AFP levels at the 5-year mark.

The Role of AFP Monitoring in Recurrence Detection

Alpha-fetoprotein serves a dual role in HCC management: as a predictor of recurrence risk when measured at the time of treatment, and as a surveillance biomarker for detecting recurrence during follow-up. While AFP has imperfect sensitivity and specificity for detecting recurrence (not all HCCs produce AFP, and AFP can be elevated due to viral hepatitis exacerbation or hepatic decompensation), a rising AFP trend after treatment is a clinically significant finding that warrants prompt imaging investigation.

Key AFP thresholds used in clinical practice include less than 20 ng/mL (normal or near-normal), 20-99 ng/mL (mildly elevated, moderate concern), 100-400 ng/mL (significantly elevated, high suspicion), and greater than 400 ng/mL or 1,000 ng/mL (markedly elevated, strong suspicion for recurrence or aggressive disease). In post-transplant surveillance, AFP is typically monitored every 3 months for the first 2 years and every 6 months thereafter. A doubling of AFP level or an absolute rise above institutional thresholds should trigger cross-sectional imaging with contrast-enhanced CT or MRI.

Cirrhosis, Fibrosis, and De Novo Tumor Risk

The severity of underlying liver disease is a critical determinant of long-term HCC recurrence risk, particularly for late recurrence. Cirrhosis creates a “field effect” in which the entire liver parenchyma is predisposed to malignant transformation through chronic inflammation, hepatocyte turnover, oxidative stress, and epigenetic alterations. Even after successful removal or ablation of the index tumor, the remaining cirrhotic liver continues to generate new tumors at a rate of approximately 3% to 5% per year.

Fibrosis staging using histological scores (METAVIR F0-F4) or non-invasive markers provides important prognostic information. The FIB-4 index, calculated from age, AST, ALT, and platelet count, is a validated surrogate for liver fibrosis that independently predicts HCC recurrence. Patients with advanced fibrosis (FIB-4 greater than 3.25) have significantly higher recurrence rates compared to those with mild fibrosis. The Child-Pugh classification (A, B, or C) and the albumin-bilirubin (ALBI) grade further refine the assessment of liver functional reserve and its impact on recurrence risk.

Liver transplantation uniquely addresses the “field effect” by removing both the tumor and the entire diseased liver. This explains why transplant recipients have the lowest recurrence rates among all curative treatment modalities. However, post-transplant immunosuppression may facilitate the growth of residual microscopic disease, and balancing adequate immunosuppression to prevent graft rejection against the risk of tumor recurrence remains an important clinical consideration.

Etiology-Specific Recurrence Considerations

The underlying cause of liver disease influences HCC recurrence patterns and risk. Hepatitis B virus (HBV) infection, the leading cause of HCC globally, is associated with HCC development even in the absence of established cirrhosis. Effective antiviral therapy with nucleos(t)ide analogs has been shown to reduce HCC recurrence risk by up to 50% in treated patients compared to untreated controls. Maintaining viral suppression (HBV DNA below detection limits) is therefore a critical component of recurrence prevention.

Hepatitis C virus (HCV) was previously a major driver of HCC, but the advent of direct-acting antiviral (DAA) therapy has transformed HCV management. Achievement of sustained virologic response (SVR) with DAA treatment reduces but does not eliminate HCC risk, particularly in patients with established cirrhosis. Current guidelines recommend continued HCC surveillance even after SVR in patients with advanced fibrosis or cirrhosis. The impact of DAA-induced SVR on recurrence risk after HCC treatment remains an area of active research, with some studies suggesting reduced recurrence while others show persistent risk.

Non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatotic liver disease (MASLD) represent an increasingly important etiology of HCC worldwide. NASH-related HCC may develop in the absence of cirrhosis in up to 20-30% of cases, complicating surveillance strategies. Alcohol-related liver disease contributes to HCC risk both through direct carcinogenic effects and through the development of cirrhosis. Addressing the underlying etiology through appropriate medical management is an essential component of recurrence risk reduction.

Post-Treatment Surveillance Recommendations

Optimal post-treatment surveillance is guided by the estimated recurrence risk. Current international guidelines generally recommend contrast-enhanced cross-sectional imaging (CT or MRI) every 3 to 6 months for the first 2 to 3 years after curative treatment, when early recurrence risk is highest. After this initial high-risk period, imaging intervals may be extended to every 6 to 12 months, depending on individual risk factors and clinical judgment.

For liver transplant recipients, the RETREAT score provides a framework for risk-stratified surveillance. Patients with a RETREAT score of 0 (less than 3% recurrence at 5 years) may require less intensive monitoring, while those with scores of 3 or higher (approximately 15-30% recurrence at 3 years) warrant more frequent imaging and AFP monitoring. High-risk patients (RETREAT score of 5 or higher) may be candidates for emerging adjuvant therapy approaches.

For patients who have undergone resection or ablation, surveillance should continue indefinitely as long as the patient remains a candidate for further treatment. Late recurrence from de novo tumors in the cirrhotic liver is an ongoing risk that persists beyond 5 years. Studies have demonstrated that even among patients who are recurrence-free at 5 years, the cumulative risk of recurrence over the next 5 years (years 5-10) is approximately 27%.

Emerging Scoring Systems and Biomarkers

Research continues to refine HCC recurrence prediction through novel biomarkers and scoring systems. AFP-L3 (the Lens culinaris agglutinin-reactive fraction of AFP) and des-gamma-carboxyprothrombin (DCP, also known as PIVKA-II) have shown promise as complementary biomarkers. A modified RETREAT score incorporating AFP-L3 (at or above 15%) and DCP (at or above 7.5 ng/mL) demonstrated improved discriminative ability with a C-statistic of 0.88, compared to 0.82 for the original RETREAT score.

The Model of Recurrence After Liver Transplantation (MORAL) uses a combination of pre-transplant factors (neutrophil-to-lymphocyte ratio, AFP, and maximum tumor diameter) and post-transplant factors (histological grade IV, vascular invasion, tumor diameter, and tumor number) to predict recurrence. The combined pre- and post-MORAL achieves a C-statistic of 0.91, representing one of the highest discriminative performances reported for any HCC recurrence prediction model.

Inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) are increasingly recognized as independent predictors of HCC recurrence. Elevated NLR (typically above 3.0 to 5.0) reflects systemic inflammation and immune dysregulation that may facilitate tumor progression and metastasis. These markers are easily obtainable from routine blood tests and add complementary prognostic information to tumor-based risk factors.

Interpreting Recurrence Risk Estimates

When interpreting the results from this calculator, several important considerations should be kept in mind. First, all risk estimates are based on population-level data and represent average probabilities. Individual outcomes may vary significantly based on factors not captured in the scoring systems, including tumor molecular biology, immune status, adequacy of treatment margins, and response to neoadjuvant or adjuvant therapies.

Second, scoring systems such as RETREAT rely in part on pathological findings (microvascular invasion, viable tumor burden) that are only available after surgery or transplantation. Pre-treatment risk estimates using imaging-based tumor characteristics and AFP levels provide useful but less precise predictions. Third, risk estimates should be considered in the context of the specific treatment received, as recurrence patterns and rates differ substantially between transplantation, resection, and ablation.

Finally, a high recurrence risk score does not mean that recurrence is inevitable, nor does a low score guarantee that recurrence will not occur. Approximately 3% to 5% of patients with the lowest risk scores still develop recurrence, while some patients with high-risk features remain disease-free. Risk scores should be used as one component of clinical decision-making, alongside patient preferences, comorbidities, functional status, and available treatment options.

Limitations of Current Risk Prediction Models

Despite significant advances in HCC recurrence prediction, current models have important limitations that clinicians and patients should understand. Most scoring systems were developed and validated in retrospective cohorts, which may be subject to selection bias and may not fully represent the diversity of HCC presentations and treatments encountered in clinical practice. The RETREAT score, for example, was developed primarily in patients who met Milan criteria by imaging before transplant, and its performance may differ in patients who underwent successful downstaging.

Geographic and ethnic variation in HCC biology also affects the generalizability of risk scores. Tumor biology differs between Asian and Western populations, in part reflecting different underlying etiologies (predominantly HBV in Asia versus HCV and NASH in Western countries). Risk scores developed in one population may not perform equally well in another, highlighting the importance of local validation studies.

Additionally, current models are largely based on static, point-in-time measurements and do not capture the dynamic nature of tumor biology and liver disease progression. Longitudinal monitoring of AFP trends, response to locoregional therapy, and changes in liver function over time may provide additional predictive power beyond what is captured in single-timepoint scoring systems. Future models incorporating molecular profiling, liquid biopsy biomarkers, and advanced imaging features (radiomics) hold promise for more personalized recurrence risk prediction.

Adjuvant and Preventive Strategies

For patients identified as high-risk for recurrence, several adjuvant and preventive strategies may be considered. Antiviral therapy for HBV and HCV has been shown to reduce recurrence risk and improve overall survival. Optimization of metabolic risk factors (diabetes control, weight management) is important for patients with NASH-related HCC. Avoidance of alcohol and hepatotoxins reduces ongoing liver injury and de novo carcinogenesis risk.

In the post-transplant setting, immunosuppression management may influence recurrence risk. Some evidence suggests that mammalian target of rapamycin (mTOR) inhibitors such as sirolimus and everolimus, which have both immunosuppressive and anti-tumor properties, may reduce HCC recurrence compared to standard calcineurin inhibitor-based regimens, although results from clinical trials have been mixed. Minimization of overall immunosuppression burden in high-risk patients is generally recommended, balanced against the risk of graft rejection.

Adjuvant systemic therapy following curative treatment remains an area of active clinical investigation. The IMbrave050 trial demonstrated that the combination of atezolizumab (an anti-PD-L1 immune checkpoint inhibitor) and bevacizumab (an anti-VEGF antibody) improved recurrence-free survival compared to active surveillance after resection or ablation in high-risk patients. Ongoing clinical trials are evaluating additional immune checkpoint inhibitors and targeted therapies in the adjuvant setting for both resection and transplant recipients.

How to Use This Calculator

This HCC Recurrence Risk Calculator integrates multiple validated scoring systems and risk factors to provide a comprehensive recurrence risk estimate. To use the calculator, enter the requested clinical parameters including treatment type, tumor characteristics (size, number, grade), vascular invasion status, AFP level, and cirrhosis status. The calculator will compute the RETREAT score (for transplant patients), the AFP-score, and provide an overall composite risk assessment based on published outcome data.

For the most accurate risk estimation, enter all available pathological data when available. If pathological information (such as microvascular invasion) is not yet available (for example, in the pre-treatment setting), the calculator will provide estimates based on the available clinical and imaging parameters. Pre-treatment estimates may be refined after pathological analysis of the surgical specimen becomes available.

The results should be discussed with your treating hepatologist, transplant surgeon, or oncologist. Risk estimates are intended to inform but not replace clinical judgment and shared decision-making between patients and their healthcare teams.

Frequently Asked Questions

Conclusion

Predicting HCC recurrence after curative treatment is a complex but essential component of comprehensive liver cancer management. Validated scoring systems such as the RETREAT score, AFP-score, and Clinical Risk Score provide frameworks for stratifying patients by recurrence risk and tailoring surveillance and treatment strategies accordingly. Key risk factors including tumor size, number, vascular invasion, AFP level, tumor grade, and underlying liver disease severity all contribute to the overall risk assessment.

This calculator integrates multiple validated approaches to provide a comprehensive recurrence risk estimate based on your specific clinical parameters. While no prediction model is perfect, using evidence-based risk stratification helps optimize post-treatment care, identify patients who may benefit from adjuvant therapies, and guide the frequency and intensity of surveillance. All results should be interpreted in collaboration with your healthcare team and considered alongside other clinical factors specific to your individual situation.

As research continues to advance our understanding of HCC biology through molecular profiling, liquid biopsy biomarkers, and artificial intelligence-enhanced imaging analysis, recurrence prediction will become increasingly personalized and precise. In the meantime, the established clinical and pathological risk factors captured in this calculator remain the foundation of evidence-based HCC recurrence risk assessment worldwide.